GlassScriptPhysician profile
Erick C Bulawa
NPI 1326020199
$2,709.72
in general payments reported to CMS, 2019-2025
32 companies · $39.44 in 2025
The $39.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $347 · 2021: $453 · 2022: $336 · 2023: $292 · 2024: $339 · 2025: $39.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $671.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $670.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $753.93 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $277.04 | 2019-2024 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $164.10 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.80 | 2019-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $149.92 | 2019-2024 | Farxiga |
| Intra-Sana Laboratories | $135.31 | 2023 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Takeda Pharmaceuticals U.S.A., INC. | $112.33 | 2019-2022 | |
| Intuitive Surgical, INC. | $94.85 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $93.54 | 2021-2023 | Imcivree |
| Mdd US Operations, LLC | $85.08 | 2019 | |
| Abbvie INC. | $83.87 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.86 | 2019 | |
| Pfizer INC. | $68.96 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $56.61 | 2019 | |
| Glaxosmithkline, LLC. | $52.59 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $42.59 | 2019 | |
| Shire North American Group INC | $40.53 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.77 | 2019-2022 | |
| Eisai INC. | $26.85 | 2020-2021 | |
| Corcept Therapeutics | $23.62 | 2024 | Korlym |
| Allergan, INC. | $19.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.23 | 2021 | |
| Currax Pharmaceuticals LLC | $16.95 | 2021 | |
| Dexcom, INC. | $16.27 | 2021 | |
| Mylan Specialty L.P. | $15.80 | 2019 | |
| Amarin Pharma, INC. | $15.42 | 2020 | |
| Redhill Biopharma INC. | $15.07 | 2023 | |
| Philips North America LLC | $14.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.77 | 2023 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.01 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erick Bulawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.